Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening?
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.18807 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Julie Mac Mahon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tallaght University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Amyloidosis, Immunoglobulin Light-chain Amyloidosis. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tallaght University Hospital, Dublin, Ireland.
- Department of Histopathology, Beaumont Hospital, Dublin, Ireland.
- Department of Histopathology, Tallaght University Hospital, Dublin, Ireland.
ORCID-Profile: Julie Mac Mahon
Zitieren
APA
Mac Mahon, J., Murray, G., McCartney, Y., Crowther, S., Tobin, A. M., & Molloy, K. (2023). Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening?. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18807
Vancouver
Mac Mahon J, Murray G, McCartney Y, Crowther S, Tobin AM, Molloy K. Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening?. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18807
BibTeX
@article{MacMahon2023,
author = {Mac Mahon, Julie and Murray, Gregg and McCartney, Yvonne and Crowther, Stephen and Tobin, Anne-Marie and Molloy, Kevin},
title = {Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening?},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.18807}
}
EUVIMED